Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineeringKathryn Michels, Shon Green, Mason Muhonen et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 108
In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligandChristopher J. Nicolai, Byoung Y. Ryu, Maura H. Parker et al.|Blood|2024Cited by 102
Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates and Tumor-Bearing Humanized MiceMaura H. Parker, Byoung Y. Ryu, Justin Theophilus Ulrich-Lewis et al.|Blood|2023Cited by 7
Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human PrimatesMaura H. Parker, Byoung Y. Ryu, Kristen Mittelsteadt et al.|Blood|2024Cited by 2
Abstract 547: Generation of synthetic cytokine receptor-induced cytotoxic innate lymphocytes (iCILs) from iPSCs as off-the-shelf cancer therapeuticsSamantha O'Hara, Ryan Larson, Teisha J. Rowland et al.|Cancer Research|2022Cited by 0